Cocrystal Pharma showcases CDI-988 at calicivirus conference, notes FDA clearance for Phase 1b challenge study

Cocrystal Pharma, Inc.

President/co-CEO Sam Lee presented CDI-988 Phase 1 data at 9th International Calicivirus Conference (Sept 7–11) in Banff.
CDI-988 is a first oral antiviral candidate for norovirus, with broad-spectrum activity against GII.4 and GII.17.
Phase 1 showed favorable safety and tolerability, with no serious adverse events.
FDA cleared a Phase 1b human challenge study for norovirus prophylaxis/treatment; expected start before end of 2025.
CDI-988 targets a conserved region in 3CL viral proteases, designed with Cocrystal's proprietary structure-based platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.